MX2023012853A - Moduladores de moleculas peque?as de la actividad de la glucocerebrosidasa y sus usos. - Google Patents

Moduladores de moleculas peque?as de la actividad de la glucocerebrosidasa y sus usos.

Info

Publication number
MX2023012853A
MX2023012853A MX2023012853A MX2023012853A MX2023012853A MX 2023012853 A MX2023012853 A MX 2023012853A MX 2023012853 A MX2023012853 A MX 2023012853A MX 2023012853 A MX2023012853 A MX 2023012853A MX 2023012853 A MX2023012853 A MX 2023012853A
Authority
MX
Mexico
Prior art keywords
disease
compounds
small molecule
molecule modulators
glucocerebrosidase activity
Prior art date
Application number
MX2023012853A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Hunt
Jianbin Zheng
Original Assignee
Vanqua Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanqua Bio Inc filed Critical Vanqua Bio Inc
Publication of MX2023012853A publication Critical patent/MX2023012853A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023012853A 2021-04-30 2022-04-28 Moduladores de moleculas peque?as de la actividad de la glucocerebrosidasa y sus usos. MX2023012853A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182734P 2021-04-30 2021-04-30
PCT/US2022/026676 WO2022232360A1 (en) 2021-04-30 2022-04-28 Small molecule modulators of glucocerebrosidase activity and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012853A true MX2023012853A (es) 2024-01-12

Family

ID=83848814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012853A MX2023012853A (es) 2021-04-30 2022-04-28 Moduladores de moleculas peque?as de la actividad de la glucocerebrosidasa y sus usos.

Country Status (10)

Country Link
US (1) US20240246952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329880A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517789A (cg-RX-API-DMAC7.html)
KR (1) KR20240016286A (cg-RX-API-DMAC7.html)
CN (1) CN117751114A (cg-RX-API-DMAC7.html)
AU (1) AU2022267285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022567A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218510A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012853A (cg-RX-API-DMAC7.html)
WO (1) WO2022232360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820204B (zh) * 2023-12-29 2026-07-24 山东百诺医药股份有限公司 R-3-苄基-3-哌啶甲酰三甲肼的制备方法
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
EP2350067A2 (en) * 2008-10-16 2011-08-03 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
US8354403B2 (en) * 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
RU2015147509A (ru) * 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
JP2016520532A (ja) * 2013-03-15 2016-07-14 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ベンゾイミダゾール誘導体およびその使用
JP2017502961A (ja) * 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
EP4039685A1 (en) * 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors

Also Published As

Publication number Publication date
CN117751114A (zh) 2024-03-22
JP2024517789A (ja) 2024-04-23
WO2022232360A1 (en) 2022-11-03
AU2022267285A1 (en) 2023-11-09
EP4329880A1 (en) 2024-03-06
BR112023022567A2 (pt) 2024-02-06
EP4329880A4 (en) 2025-03-05
KR20240016286A (ko) 2024-02-06
CA3218510A1 (en) 2022-11-03
US20240246952A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
MX2023012882A (es) Moduladores de moleculas peque?as de la actividad de la glucocerebrosidasa y sus usos.
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
MX2024004581A (es) Moduladores de micromoleculas de la actividad de la glucocerebrosidasa y usos de estos.
SA522441561B1 (ar) مُعدلات ليباز أُحادِيُّ الجلِيسِريد
BR112022002683A2 (pt) Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
WO2019070891A8 (en) Gene therapies for lysosomal disorders
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
MA51625B1 (fr) Procédé de production de modulateurs de somatostatine
ATE289800T1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
BR112023022567A2 (pt) Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos
MX2024015843A (es) Moduladores de cinasa y metodos de uso de los mismos
WO2023178280A3 (en) Compositions and methods for modulating alpha-synuclein expression
WO2022251212A3 (en) Uses of a somatostatin modulator for the treatment of disease
WO2020068950A8 (en) Hdac1,2 inhibitors
MX2021009383A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2022013173A (es) Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
AR127356A1 (es) Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos
WO2022246204A3 (en) Compounds for reducing ptbp1 expression
WO2022235551A3 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis
WO2025030006A3 (en) Protein tyrosine phosphatase degraders and uses thereof
BR112022006125A2 (pt) Composições compreendendo hialuronidase e/ou colagenase e/ou 4-metilumbeliferona (4-mu) e métodos de tratamento usando as mesmas
CL2025000489A1 (es) Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos
WO2024042363A8 (en) Tyk2 inhibitors and uses thereof